Waning antibodies in SARS-CoV-2 naïve vaccinees: Results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers

J Infect. 2021 Sep;83(3):381-412. doi: 10.1016/j.jinf.2021.06.017. Epub 2021 Jun 20.

Authors

Marie Tré-Hardy¹, Roberto Cupaiolo², Alain Wilmet², Ingrid Beukinga², Laurent Blairon²

Affiliations

¹ Department of Laboratory Medicine, Iris Hospitals South, rue Jean Paquot 63, Brussels 1050, Belgium; Faculty of Medicine, Université libre de bruxelles, Brussels, Belgium; Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Belgium. Electronic address: mtrehardy@his-izz.be.
² Department of Laboratory Medicine, Iris Hospitals South, rue Jean Paquot 63, Brussels 1050, Belgium.

No abstract available

Keywords: Covid-19; Efficacy; Immunogenicity; SARS-CoV-2; mRNA-1273 vaccine.

Publication types

Letter
Comment

MeSH terms

2019-nCoV Vaccine mRNA-1273
Antibodies, Viral
COVID-19 Vaccines
COVID-19*
Health Personnel
Humans
Immunogenicity, Vaccine
SARS-CoV-2*

Substances

Antibodies, Viral
COVID-19 Vaccines
2019-nCoV Vaccine mRNA-1273